Asia Pacific

China Evergrande Group’s dollar bonds rebounded on Monday morning after tumbling late last week. But the poor performance of the company’s bonds appears to have spread to outstanding notes from other Chinese property companies.

South Korea's Big Hit Entertainment, the talent manager behind globally-popular boy band BTS, has sealed the country’s largest listing in three years as investors continue to flock to Korea's IPO market.

Singaporean agribusiness Olam International has become the latest borrower in the country to offer a loan linked to the Singapore overnight rate average (Sora), a new benchmark.

JD Health International, the healthcare unit of Chinese e-commerce company JD.com, has submitted an IPO application to Hong Kong’s stock exchange.

Kaspi, the Kazakh fintech and e-commerce firm, has returned to the IPO market for a second attempt at a London listing after cancelling last year's effort over valuation differences between investors and the sellers. Sources say that gap has been bridged and are confident of listing Kaspi this year.

China Yangtze Power has raised $1.8bn from a smaller-than-expected offer of Global Depositary Receipts in London, sealing only the third listing through the London-Shanghai Stock Connect scheme.

In this round-up, Xi Jinping reveals plans for the country to become carbon neutral by 2060, FTSE Russell decides to include Chinese government bonds in its flagship index, and the State Administration of Foreign Exchange resumes granting new outbound investment quotas.

FTSE Russell plans to add Chinese government bonds to its flagship FTSE World Government Bond Index (WGBI) next year, a move that is expected to provide investors further access to the world’s second largest bond market.

The government of Pakistan is seeking banks to offer advice on the sale of planned dollar bonds and sukuk in the international capital market.

China’s Minth Group, an auto parts company, has closed its debut loan at a bigger size of $200m.

Korean video game publisher Krafton has invited local and international banks to pitch for a spot on its IPO.

Biopharmaceutical firm Everest Medicines has hit the road for its up to HK$3.5bn ($451m) Hong Kong IPO.